To access the effectiveness, safety and tolerance of methotrexate (MTX) in psoriatic arthritis (PsA) treatment.
Introduction
The incidence rate of psoriatic arthritis is 6-42%. Among drugs treating psoriatic arthritis, methotrexate (MTX) is approved by the Food and Drug Administration (FDA) in psoriatic arthritis treatment. Although the efficacy of MTX is variable among researches, it is the drug recommended by European League against Rheumatism-EULAR for moderate and severe psoriatic arthritis treatment [1] .
Methods
Because of the absence of research or summary report on MTX in the treatment of psoriatic arthritis in Vietnam, we recruited 37 psoriasis arthritis patients, Between January 2016 to March 2017, admitted to HCMC Hospital of Dermato-Venereology.
Results
Female made up the majority (67.57%), more than male. 15.6% of patients had the family history of psoriasis as shown in Table 1 . Most cases (70.27%) had skin psoriasis before arthritis. Joint deformity rate was high (37.0%). Peripheral arthritis rate was also significant (81.08%), and the next was distal interphalangeal joint arthritis (31.3%). Nail dystrophy was also familiar (83.78%). Positive HLA-B27 and HLA-DR7 percentage was 32.5% and 32.4% respectively while the positivity for HLA Cw06 in our research was 2.7%.
Every patient stopped therapy with NSAIDs (non-steroidal anti-inflammatory drugs) and with DMARD (disease-modifying antirheumatic drug) at least 2 weeks and 1 month before, respectively. After 12 weeks treatment by MTX, at dosage 10-15mg PO q12hr for 3 sequential doses per week. 5 mg Folic acid was used 24 hours after taking MTX; skin lesions were improved. 40.5%, 24.3% and 37.8% achieved PASI 50, PASI 75 and PASI 90, respectively as shown in Table 2 , in comparison with Laura's study in which 27.2% patients reached PASI 75 [2] . The side effects at week 12 were mostly nausea and vomiting (8.1%). Fatigue and alopecia had the same rate (2.7%). These side effects were transient, and there was no need for treatment. Other side effects noted were elevated SGPT (2.7%), hemoglobin decreased (2.7%), neutropenia (2.7%) ( Table 3) . 
Discussion
Female was twice as likely as a man to get psoriatic arthritis, which was higher than the result of Reich's study suggesting the proportion of males was 58% [3] . This difference may be the characteristic of psoriatic arthritis in Vietnam because psoriasis relates to genetic and races.
Joint deformity rate was also significant (37%) which was higher than the rate suggested in Moll and Wright research, 5% [4] . Nail dystrophy rate was 83.78% which was compatible with those of Scarpa, 63% [4] So patient with psoriasis vulgaris having nail change should be monitored to discover arthritis. The psoriatic arthritis duration was about 0.8 (0.1-2.9) year on median which is lower than the study of Gabrielle et al., (1-5) year on median) [5] . So most of our patients had suffered from prolonged arthritis before we did our research.
Based upon our and published experiences, MTX is effective and affordable in psoriatic arthritis, affecting both skin lesions and joint damage. The price is more affordable than many biologic agents [6] , [7] , [8] , [9] , [10] , [11] , [12] .
We finally demonstrated that the rate of treatment response in Vietnam is the same as demonstrated by foreign authors in other countries.
